Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models.
- Resource Type
- Article
- Authors
- Tkachuk, A. P.; Gushchin, V. A.; Potapov, V. D.; Demidenko, A. V.; Lunin, V. G.; Gintsburg, A. L.
- Source
- PLoS ONE. 4/28/2017, Vol. 12 Issue 4, p1-16. 16p.
- Subject
- *BCG vaccines
*GUINEA pigs as laboratory animals
*IMMUNOLOGICAL adjuvants
*THERAPEUTIC immobilization
*BOOSTER vaccines
ANIMAL models of tuberculosis
- Language
- ISSN
- 1932-6203
New innovative vaccines are highly needed to combat the global threat posed by tuberculosis. Efficient components–antigens and adjuvants–are crucial for development of modern recombinant TB vaccines. This study describes a new vaccine (GamTBvac) consisting of two mycobacterial antigen fusions (Ag85A and ESAT6-CFP10)–with dextran-binding domain immobilized on dextran and mixed with an adjuvant consisting of DEAE-dextran core, and with CpG oligodeoxynucleotides (TLR9 agonists). GamTBvac and its components were assessed for immunogenicity and protective efficacy in GamTBvac-prime/boost and BCG-prime/ GamTBvac-boost in murine and guinea pig TB models. Results show that in both infectious models, GamTBvac has a strong immunogenicity and significant protective effect against Mycobacterium tuberculosis strain H37Rv under aerosol and intravenous challenges. GamTBvac showed a particularly strong protective effect as a BCG booster vaccine. [ABSTRACT FROM AUTHOR]